We are excited to welcome?Michael Ehlers, MD, PhD, an accomplished R&D leader and executive, to the MPM BioImpact team as an Entrepreneur Partner! Mike will work alongside our expert scientists and investment professionals to build and progress companies advancing leading technologies and driving patient breakthroughs. Read more here:
MPM BioImpact
风险投资与私募股权管理人
Boston，Massachusetts 7,835 位关注者
Building Companies to Transform Patient Outcomes
关于我们
MPM BioImpact is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. MPM BioImpact invests across the biotech landscape from early stage start-ups to public companies.
- 网站
-
https://www.mpmcapital.com/
MPM BioImpact的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- Boston，Massachusetts
- 类型
- 合营企业
- 领域
- Cancer Therapy、Disease Treatment、Funding companies to make a difference、Pharmaceuticals、Investment、Biotech、Venture Creation和Therapeutics
地点
MPM BioImpact员工
动态
-
Today, Aktis Oncology, a company founded and launched by MPM BioImpact, announced the closing of its $175M oversubscribed Series B financing. Aktis Oncology is a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors.?Congratulations to the Aktis team!??
We are pleased to share that?Aktis?closed a $175 million Series B?financing. The financing was led by RA Capital Management, and co-led by RTW Investments, Janus Henderson Investors, and was joined by a select syndicate of additional new investors, including funds and accounts advised by?T.Rowe?Price Associates, Inc., Avidity Partners, and an undisclosed life sciences-focused investment fund. Proceeds raised will be used to further advance our radiopharmaceuticals pipeline, including our first-in-class Nectin-4-targeted miniprotein radioconjugate. To read more, visit https://lnkd.in/eYANNP84
-
-
???A*STAR & MPM BioImpact: Building Biotech Spinoffs Together ? MPM BioImpact is excited to announce and begin our partnership with ASTAR to build global biotech companies together!? ? Special thanks to Irene Cheong,?Daphne Wong, and Su Ling Yeo for hosting Ansbert Gadicke, M.D. and David Kolesky.? ? #medicines #Singapore #MPMBioImpact
?? A*STAR & MPM BioImpact: Building Biotech Spinoffs Together A*STAR is excited to partner with MPM BioImpact to venture build globally investible biotech spinoffs. Thank you Dr Ansbert Gadicke, M.D., Founder and Managing Partner at MPM BioImpact and Dr David Kolesky, Principal at MPM BioImpact for the engaging fireside chat with Irene Cheong, Senior Executive Director, A*STAR Innovation & Enterprise (Venture Creation & Growth and Human Health & Potential) on venture-building, and for sharing valuable insights with our aspiring scientist-founders! Over 100 A*STAR scientists and ecosystem partners including ClavystBio, EDBI Pte Ltd, Enterprise Singapore, SGInnovate and National Research Foundation Singapore joined us for today’s fireside chat and networking lunch. A*STAR will continue to collaborate with our ecosystem partners to support the growth of biotech spinoffs and pave the way for groundbreaking #biotech innovations. Stay tuned for updates and be part of this remarkable venture building journey with us! Wendy Wu Jie Yee-Chia Yeo Su Ling Yeo Daphne Wong #DeepTechVentureBuilding #StartUpJourney #Innovation #CreatingGrowth #ASTARforEnterprise #ASTARforIndustry
-
-
-
-
-
+4
-
-
We are #recruiting a Senior Director / Director of Relationship Management to our team at MPM BioImpact. View our job posting to learn more.
-
Orna Therapeutics and ReNAgade Therapeutics - two portfolio companies built by MPM BioImpact - have joined forces, uniting the leading circular RNA technology (oRNA) for in vivo CARs with best-in-class lipid nanoparticle (LNP) delivery solutions for RNA.? This strategic acquisition will enable RNA therapeutics for diseases with major unmet needs. Learn more: https://lnkd.in/eYHYAfkf
-
-
Our friend and colleague, Ivan Cheung,?CEO of our portfolio company NextPoint Therapeutics, Inc., has been named to TIME magazine's top 100 most influential people in global health. It is an honor to work beside you, Ivan!
We are proud to share that our CEO Ivan Cheung has been named to the 2024 #TIME100HEALTH list by TIME, which recognizes the 100 most influential people in global health. “Ivan has demonstrated a relentless commitment to translating scientific breakthroughs into tangible solutions that benefit patients worldwide. The well-deserved recognition by TIME underscores his outstanding contributions to public health and exemplifies his visionary leadership and unwavering dedication to improving the lives of patients.” - Detlev Biniszkiewicz, PhD, Managing Director at MPM BioImpact and Chairman of NextPoint’s Board of Directors. Under Ivan’s leadership, NextPoint is advancing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, so that we can improve treatment options for cancer patients including those who do not benefit from PD-1/L1 therapy. Read the full announcement at https://nextpointtx.com/.?
-
-
Congratulations?to our portfolio company, Reunion Neuroscience, on the announcement of their $103M Series A Financing co-led by Novo Holdings! In August 2023, MPM BioImpact acquired Reunion Neuroscience. As part of our portfolio, Reunion Neuroscience is continuing their mission of developing the next-generation of therapeutics for underserved mental health disorders.
Today, Reunion Neuroscience announced the closing of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings. The financing will support the RECONNECT Phase 2 clinical trial for RE104 in #postpartumdepression and expansion into other psychiatric indications of high unmet need, including adjustment disorder in #cancer. RE104 is a proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders. Read the press release: https://bit.ly/3Wj5fyF
-
-
Upon joining our portfolio company Orna Therapeutics as Chief Medical Officer later this month, Frank Neumann, MD, PhD, will join MPM BioImpact as an Entrepreneur Partner, working with our diverse team of scientists and investment professionals developing therapies for diseases with high unmet needs. Learn more about Dr. Neumann:?https://lnkd.in/eQhAaYxv
-
-
MPM BioImpact Co-Managing Partner, Christiana Bardon M.D., was quoted in The Wall Street Journal this morning, in an article titled “Investors Flock Back to Biotech After a Long, Cold Spell".?Worth the quick read!
I was quoted in The Wall Street Journal this morning in an article, "Investors Flock Back to Biotech After a Long, Cold Spell". After a three year meltdown in the markets, fingers crossed that our industry will start to get attention for its great progress. https://lnkd.in/gc95nasc
Investors Flock Back to Biotech After a Long, Cold Spell
wsj.com
-
Congratulations to Frontier Medicines on their continued progress – today announcing their first patient dosed with FMC-376 alongside their Series C financing which will support the advancement of multiple programs into clinical studies!
? Today we announced the close of our oversubscribed $80 million Series C financing co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management.? We also announced the first participant dosed with FMC-376, the first therapeutic candidate discovered with the Frontier? Platform. ? Learn more here: https://lnkd.in/esgxPc7X #biotech, #precisionmedicines, #oncology
-